T&R Biofab selected for 13 billion won national project to develop AI bioink platform

T&R Biofab, a South Korean regenerative medicine company specializing in 3D bioprinting, has been selected for a national R&D project led by the Ministry of Science and ICT. The project, titled "AI Bioink Platform Development," has a total budget of 13 billion won (~$9.7 million), with 9.5 billion won in government funding. T&R Biofab will participate as a joint research organization alongside POSTECH (Pohang University of Science and Technology), which serves as the lead institution. The project runs through December 2030, focusing on creating an integrated platform that combines AI, tissue engineering, and bioprinting to design and validate organ-specific bioinks.

This announcement is significant for the bioprinting field because it addresses one of the most persistent bottlenecks: batch-to-batch variability and lack of standardized, organ-specific bioinks. T&R Biofab’s role involves establishing extraction processes for skin- and blood-vessel-specific decellularized extracellular matrix (ECM) and scaling up bioink production. By integrating AI-driven feedback loops, the platform aims to reduce development time and improve reproducibility—moving beyond the experience-based trial-and-error methods that have limited clinical translation. The project also echoes a broader trend in South Korea, where government-backed consortia are accelerating the convergence of AI and biomanufacturing to secure leadership in next-generation medical devices.

What matters now is execution. T&R Biofab already has commercial footing with ECM-based wound dressings and hemostatic agents, plus a U.S. patent for 3D-printed cranial implants. This project requires them to prove AI can materially reduce bioink variability at scale, not just in a lab setting. With 5 years and 13 billion won, the company must deliver a platform that is not only scientifically robust but also translatable into certified production—especially if it intends to supply organoid or pharmaceutical evaluation markets. The ecosystem will watch whether the AI-bioprinting feedback loop can move from concept to qualified output within the project’s timeline.